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Trichloroethylene (TCE) and related hydrocarbons constitute an important class of environmental
pollutants whose adverse effects on liver, kidney, and other tissues may, in part, be mediated by
peroxisome proliferator-activated receptors (PPARs), ligand-activated transcription factors
belonging to the steroid receptor superfamily. Activation of PPAR induces a dramatic proliferation
of peroxisomes in rodent hepatocytes and ultimately leads to hepatocellular carcinoma. To
elucidate the role of PPAR in the pathophysiologic effects of TCE and its metabolites, it is
important to understand the mechanisms whereby PPAR is activated both by TCE and
endogenous peroxisome proliferators. The investigations summarized in this article a) help clarify
the mechanism by which TCE and its metabolites induce peroxisome proliferation and b) explore
the potential role of the adrenal steroid and anticarcinogen dehydroepiandrosterone 3p-sulfate
(DHEA-S) as an endogenous PPAR activator. Transient transfection studies have demonstrated
that the TCE metabolites trichloroacetate and dichloroacetate both activate PPARx, a major liver-
expressed receptor isoform. TCE itself was inactive when tested over the same concentration
range, suggesting that its acidic metabolites mediate the peroxisome proliferative potential of
TCE. Although DHEA-S is an active peroxisome proliferator in vivo, this steroid does not stimulate
trans-activation of PPARa or of two other PPAR isoforms, y and 6/Nucl, when evaluated in COS-1
cell transfection studies. To test whether PPARa mediates peroxisomal gene induction by DHEA-S
in intact animals, DHEA-S has been administered to mice lacking a functional PPARa gene. DHEA-
S was thus shown to markedly increase hepatic expression of two microsomal P4504A proteins
associated with the peroxisomal proliferative response in wild-type mice. In contrast, DHEA-S did
not induce these hepatic proteins in PPARa-deficient mice. Thus, despite its unresponsiveness to
steroidal peroxisome proliferators in transfection assays, PPARa is an obligatory mediator of
DHEA-S-stimulated hepatic peroxisomal gene induction. DHEA-S, or one of its metabolites, may
thus serve as an important endogenous regulator of liver peroxisomal enzyme expression.
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Introduction
Trichloroethylene (TCE) is a widely used associated with a number ofseveral adverse
agent in dry cleaning, paint stripping, and health effects, including liver, kidney, and
industrial cleaning that is of particular central nervous system toxicity (2). The tox-
interest to Superfund deanup efforts. It is a icity of these chemicals appears to be
common and persistent environmental enhanced by their metabolism catalyzed by
pollutant, and has been found in over one- liver cytochrome P450 (CYP) enzymes,
third ofhazardous waste sites and in 10% of which produce multiple reactive and/or
groundwater sources (1). Exposure to TCE toxic metabolites (3). These metabolites
and related chlorinated hydrocarbons is may act, at least in part, via peroxisome
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proliferator-activated receptor (PPAR), a
ligand-activated transcription factor that
belongs to the steroid receptor superfamily
(4). Three mammalian PPAR subtypes, (X,
6 (or Nuci,) and y, have been identified.
Gene knockout studies in the mouse model
demonstrate that PPARa, which is highly
expressed in liver, is responsible for the pro-
liferative effects of chemical peroxisome
proliferators such as clofibrate (5). By con-
trast, PPAR8/Nucl is expressed in many
cell types, whereas PPARy is abundant in
adipose tissues where it plays an important
role in adipocyte differentiation (6). The
present study investigates the role ofTCE
and its metabolites in activation ofPPAR
protein using a transient transfection assay.
As reported below, the peroxisome prolifer-
ative effects of TCE are mediated by
PPARa via its interactions with TCE's
acidic metabolites, trichloroacetic acid
(TCA), and dichloroacetic acid (DCA).
To elucidate the role of PPAR in the
pathophysiologic effects of TCE and its
metabolites, it is additionally important to
understand the physiologic effects of
PPARa activation by endogenous regula-
tors. Such information may help identify
any synergistic or antagonistic interactions
between endogenous peroxisome prolifera-
tors and chlorinated hydrocarbons at the
level of PPAR receptor activation. One
such potential endogenous PPAR activator
is dehydroepiandrosterone (DHEA), a nat-
urally occurring adrenal steroid with known
peroxisome proliferative potential (7).
DHEA is distinguished from other steroids
by its chemoprotective properties (8,9).
DHEA can also stimulate a dramatic
increase in both the size and number of
peroxisomes in liver when given to rodents
at high doses. This response is accompanied
by a substantial increase in peroxisomal
5-oxidation and fatty acid-metabolizing
CYP4A enzymes (10-14). Moreover,
chronic administration of DHEA can lead
to hepatocarcinogenesis (15). The cellular
mechanism(s) underlying the DHEA-
induced peroxisome proliferative effect is
poorly understood. In primary rat hepato-
cytes, DHEA is inactive as a peroxisome
proliferator unless it is first metabolized to
the corresponding 31-sulfate (DHEA-S)
(16,17). Recent studies on male workers
chronically exposed to TCE have shown
that increased plasma levels ofDHEA-S are
associated with years ofexposure to TCE,
rising from 255 to 718 ng/ml for workers
exposed to TCE for less than 3 and greater
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than or equal to 7 years, respectively (18).
This relationship between DHEA-S and
TCE suggests that TCE may disrupt
peripheral endocrine function, perhaps
through its peroxisome proliferative effects
in liver and other tissues. In addition, it is
conceivable that TCE may compete with
DHEA-S for binding to PPAR, ultimately
stimulating an elevation ofplasma DHEA-
S as a compensatory response. More studies
are required to elucidate the mechanism
underlying these interactions between TCE
and DHEA-S and the potential role of
PPAR and peroxisome proliferation in
these events.
As is the case for chlorinated hydro-
carbons such as TCE, peroxisome prolifera-
tion induced by endogenous fatty acids, as
well as by structurally diverse hypolipi-
demic fibrate drugs and other foreign
chemicals, is mediated by the a isoform of
PPAR, PPARa (19). However, as described
below, unlike the TCE metabolites tri-
chloroacetate and dichloroacetate, DHEA
and DHEA-S fail to activate PPARa in
transient cotransfection assays. It is possible
that DHEA and/or DHEA-S might medi-
ate their effects through other related
receptors, specifically, PPARy (20) or
PPAR6/Nucl (21). Alternatively, the in
vitro transfection systems used to test for
DHEA and/or DHEA-S activation of
PPARa may be insufficiently sensitive to
detect weak activation by the steroid or
may lack metabolic capacity or other key
factors present only in the intact animal.
Several of these possibilities have been
examined recently (22), alongwith the role
of PPARa in DHEA-S-induced peroxi-
some proliferation in vivo using a mouse
line that lacks the PPARa receptor (5) and
its associated pleiotropic response to perox-
isome proliferators. These studies are sum-
marized below. The results establish that
despite its apparent inactivity in vitro,
PPARa mediates the in vivo effects of
DHEA-S on peroxisomal proliferation.
Materials and Methods
Plumids
Reporter plasmid pLucA6-880, containing
880 nts (nucleotides) of 5'-flanking DNA
of the rabbit CYP4A6gene cloned into
pl9Luc, and the mouse PPARa expression
plasmids pCMV-PPARa and pCMV-
PPARa-G (23) were kindly provided by
E. Johnson (The Scripps Research Institute,
La Jolla, CA). A plasmid expressing full-
length human PPAR6/Nucl cloned into
pJ3omega (21) was kindly provided by A.
Schmidt (Merck Research Labs, West
Point, PA). Mouse PPARy cloned into
pSV-Sportl (24) was provided byJ. Reddy
(Northwestern University Medical School,
Chicago, IL) and mouse RXRa expression
plasmid pCMX-mRXRac (25) was pro-
vided by R. Evans (Salk Institute, San
Diego, CA). P-Galactosidase expression
plasmid (pSV-P-gal) was purchased from
Promega (Madison, WI).
TransfectionStudies
Transfection ofCOS-1 cells grown in 12-
well tissue culture plates was carried out by
a calcium phosphate precipitation method.
After transfection, cells were incubated in
Dulbecco's modified Eagle's medium
(DMEM) containing 10% charcoal-
stripped, delipidated bovine calf serum.
Transfections were performed as described
elsewhere (22) using a P-galactosidase
plasmid as an internal control. Chlorinated
hydrocarbons, including TCE, TCA,
and DCA, were purchased from Aldrich
Chemical Co. (Milwaukee, WI) and were
dissolved in DMEM before administered
to cells. Potential PPAR activators, includ-
ing Wy-14,643, DHEA-S, DHEA, and
ADIOL were purchased from Sigma
Chemical Co. (St. Louis, MO), each
diluted from a 1000-fold stock in dimethyl
sulfoxide. Chemicals were added to the
cells in fresh media 24 hr after transfection
at the concentrations indicated. Forty-eight
hours after initiating the transfection, cells
were washed twice with cold phosphate-
buffered saline, then dissolved by incuba-
tion for 15 min at 4°C in lysis solution
(100 mM KPi, pH 7.8, 0.2% Triton X-
100, with 1 mM dithiothreitol added prior
to use; 80 pl/well). The cell extract was
then scraped and transferred to a centrifuge
tube for removal ofinsoluble cell debris in
an Eppendorfcentrifuge. Luciferase and ,B-
galactosidase activities were measured.
Luciferase activity values were normalized
for transfection efficiency using ,-galac-
tosidase activity values determined from
the same preparation ofcell lysate.
PPARKnockoutMice
Male PPARa (-/-) mice or (+/+) (F3
homozygotes or wild-type; hybrids of
C57BL/6N x ISV129 genetic background;
10-12 weeks ofage) (5) were injected with
either DHEA-S or clofibrate (Sigma) at 15
mg/100 g body weight or corn oil (vehicle
control) for 4 consecutive days by
intraperitoneal injection (22). Twenty-four
hours after the final injection, mice were
killed by carbon dioxide asphyxiation, and
the liver and kidneys were removed and
used for isolation ofmicrosomes.
AnalysisofMicrsomalCYP4A
ProteinExpression
Liver microsomes prepared from frozen
tissues by differential centrifugation were
analyzed by Western blotting using poly-
clonal antirat CYP4A antibody raised to a
di(2-ethylhexyl)phthalate-inducible rat
liver CYP4A protein related to CYP4A1.
This antibody has been characterized else-
where (27) and was provided by R.T.
Okita (Washington State University,
Pullman, WA).
Results
ChlorinatedHydrocarbons and
Peroxisome Proliferation
Rodent bioassays establish that TCE is a
complete hepatocarcinogen, with chronic
exposure to TCE leading to hepatocellular
carcinoma development (28,29). The
hepatotoxicity and carcinogenicity ofTCE
appears to be related directly to the extent
of its oxidative metabolism, which is pri-
marily catalyzed by liver CYP enzymes and
yields multiple reactive and toxic meta-
bolites (Figure 1). At least some of these
active metabolites may achieve their delete-
rious effects via a mechanism that involves
peroxisome proliferation (28). Peroxisome
proliferation is a trophic phenomenon in
the liver, originally described after admin-
istration ofthe hypolipidemic drug clofi-
brate to rodents (30). This proliferative
response is characterized in the short term
by a dramatic increase in both the size and
number of peroxisomes. It is also associ-
ated with upregulation of peroxisomal
fatty acid n-oxidation enzymes and micro-
somal P4504A fatty acid hydroxylase
enzymes as well as increased cell differenti-
ation and liver weight gain. Chronic expo-
sure to peroxisome proliferators leads to
hepatocellular carcinoma. A broad spec-
trum ofstructurally diverse compounds,
including certain hypolipidemic drugs,
herbicides, industrial solvents, and the
adrenal steroid DHEA, has been shown to
induce peroxisome proliferation. These
peroxisome proliferators stimulate liver
growth and tumor formation by a nongeno-
toxic mechanism, i.e., one that does not
involve DNA damage caused by the peroxi-
some proliferators or their metabolites (31).
PPAR, a ligand-activated transcription fac-
tor and a member of the steroid receptor
superfamily, has been shown to be activated
by diverse peroxisome proliferators and can
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Figure 1. Pathways ofP450-dependent metabolism ofTCE and PCE.
thus mediate their peroxisome proliferative
effects (19).
ActivationofPPARabyChlorinated
Hydrocarbons
Trichloroacetic acid and dichloroacetic acid
are secondary metabolites ofTCE (32).
TCA, in particular, has been implicated as a
key hepatocarcinogenic metabolite ofTCE
and is believed to act by inducing peroxi-
some proliferation (33). Transient trans-
activation assays using chimeric receptors
(ER/PPARa and GR/PPARa) containing a
PPARa transactivation domain suggest that
TCA may be a weak activator ofPPARat
(19). To investigate the responsiveness of
PPAR to activation by TCE and its acidic
metabolites, TCA and DCA, COS-1 cells
were cotransfected with a PPAR expression
plasmid, pCMV-mPPARa, together with a
reporter plasmid containing a peroxisome
proliferator response element, pLuc4A6-
880 (23). As shown in Table 1, treatment
ofthe transfected COS-1 cells with TCA
and DCA for 24 hr resulted in the activa-
tion ofa luciferase reporter gene. This acti-
vation was not apparent at 0.1 mM TCAor
0.1 mM DCA, but was readily seen at the
two higher concentrations tested, 1 and 5
mM. Activations of 16- and 10-fold,
respectively, were observed with TCA and
DCA at concentrations of 5 mM. When
tested over the same concentration range,
TCE alone did not substantially activate
reporter gene expression (Table 1). These
results indicate that the PPARa-dependent
effects ofTCE on gene expression most
likely proceed through its oxidative
metabolites TCA and DCA. The specific
P450 enzymes that catalyze the oxidative
metabolism ofTCE, and that ultimately
yield TCA and DCA, may thus play a crit-
ical role in the activation of TCE to
metabolites that contribute to its deleteri-
ous effects on liver, kidney, and perhaps
other tissues.
DHEA-S-Induced CYP4A
Induction in Vivo
Dehydroepiandrosterone is a naturally
occurring steroid hormone that has various
beneficial effects on rodents, including
antidiabetic, anticarcinogenic, and antiobe-
sity effects. DHEA has been characterized
as a peroxisome proliferator (7). At phar-
macologic doses, DHEA induces peroxi-
some proliferation, with an increased
expression of peroxisomal ,-oxidation
enzymes and some other enzymes involved
in lipid metabolism such as microsomal
CYP4A enzymes. Like other peroxisome
proliferators, DHEA can induce hepatocar-
cinogenesis when administrated to rodents
at moderate to high doses. The apparent
peroxisome proliferative effect ofDHEA in
intact animals and its ineffectiveness at
inducing peroxisomal gene expression in
cultured hepatocytes (16,17) suggest that
DHEA undergoes metabolism in vivo to an
active derivative that mediates the peroxi-
some proliferative response. The finding
that the sulfate ofDHEA, DHEA-S, is an
active inducer ofperoxisomal enzyme and
CYP4A expression in hepatocyte culture
(16) raised the possibility that DHEA sul-
fation, catalyzed by liver sulfotransferase
enzymes, is a prerequisite for DHEA to
attain its peroxisome proliferative effects.
To investigate this possibility, studies were
conducted to determine whether DHEA-S
is preferred to DHEA with respect to
CYP4A induction in vivo (22). DHEA-S
given at a low dose (10 mg/kg daily for 4
days) was found to be substantially more
active than DHEA with respect to liver
CYP4A3 mRNA induction. This finding is
consistent with the observation that aceta-
minophen, an inhibitor ofsulfate conjuga-
tion, reduces the peroxisomal n-oxidation
activity induced by DHEA, but does not
affect the activity induced by DHEA-S and
clofibrate (17). By contrast, at a higher
dose ofsteroid (60 mg/kg), DHEA and
DHEA-S were equally active at inducing a
Table 1. Activation of PPARa bychlorinated hydrocarbons. Normalized luciferase activity, fold increase.
Concentration, mM Trichloroacetic acid Dichloroacetic acid Trichloroethylene
Control 1.00 1.00 1.00
0.1 1.06±0.11 1.31 ±0.11 1.27
1.0 8.14±1.56 4.18±0.37 1.74±0.54
5.0 16.54±0.04 10.94±1.24 1.72±0.25
Cotransfection of PPARa expression plasmid with a P4504A6 promoter-luciferase reporter construct was carried
out in COS-1 monkey kidney cells using a calcium phosphate precipitation method. Cells were treated with either
TCA, DCA, orTCE, as indicated, for a 24-hrperiod beginning 24 hrafterwashing ofthe cells to remove the calcium
phosphate DNA precipitate. Luciferase reporter activity of cell extracts was then determined and the data were
normalized to a ,-galactosidase reporter(pSV-0-gal) as an internal standard. Data shown are mean ± range for
duplicate determinations.
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involve endogenous regulators that may
serve to modulate PPARa activity. Char-
acterization of the physiologic role of
PPARa in responding to these endogenous
i | activators is thus critical for a full under-
standing of the pathophysiologic effects of
foreign peroxisome proliferators, including
i- W TCE and its metabolites. Endogenous
PPARo activators derived from fatty acids
and their metabolites have been described
and include linoleic acids, polyunsatured
PPARa PPAR+Ra fatty acids, and eicosanoids (34-36). By
M Vehicle control DHEA-S(1001M contrast, steroidal activators of PPAR have
*v14A43E20}tM 7-keto DHEAI100^MI not been identified. In view ofits peroxiso-
*_DNEA(1U5t)M 9ADIOL-S(100 LM) mal proliferative effects in vivo, DHEA-S is
R -a good candidate for an endogenous
steroidal PPARa activator. Studies were
therefore conducted to investigate the role
of PPARa in DHEA-S-activated peroxi-
some proliferation using transient transfec-
tion methods (22). Unlike the prototypic
foreign chemical peroxisome proliferator
Wy-14,643, which can induce luciferase
reporter activity by 15-fold after 24-hr
treatment of PPARa-transfected COS-1
cells, DHEA-S was unable to induce
reporter activity. DHEA, and the related
steroids 7-keto-DHEA and ADIOL-S were
-PPAAa +PPARa +PPARac- also inactive in terms of induction of
PPARa-stimulated reporter activity
Activation of PPARa by peroxisome prolifer- (Fi ure2A)r
:ransfection of PPARa or PPARa-G expression gu.2A).
with P4504A6 promoter-luciferase reporter Retinoid X receptor (RXR) is a common
(4A6-Luc) in the presence or absence of an partner for many steroid receptors. RXR
pression plasmid was carried out in COS-1 forms a heterodimer with PPAR and this
g calcium phosphate precipitation method. heterodimerization enhanced PPAR-DNA
treated with the indicated PPAR activators binding and transcriptional activation activ-
Luciferase reporter activity was then deter- ity (37). To investigate whether RXR is
d the data normalized to a P-galactosidase required for DHEA-S-induced PPAR acti-
(pSV-J-gal) as an internal standard. Data vation, a mouse RXRa expression plasmid
e mean ± range (n=2) or mean ± SD (n=3) was cotransfected with pCMV-PPARa As
replicate independent samples. COS-1 cells was pciVePase .. shown in Figure 2A basal luciferase reporter a low level of endogenous receptor activity S. . .
first bar in B), but a comparatively high level activity was increased 3-fold in cells trans-
enous PPARa activator (PPARa + 4A6Luc + fected with RXRa. However, no further
ntrol). This endogenous activatoractivity was increase in activity was detected after treat-
educed when using the mouse PPARa-G ment of the transfected cells with DHEA,
). Both receptors were strongly activated by 7-keto DHEA, DHEA-S, orADIOL-S.
3 but not by DHEA-S, DHEA, 7-keto DHEA, or Transfection of PPARa expression plas-
-sulfate. mid results in a substantial increase in basal
luciferase reporter activity in the absence of
me proliferative response (22). The peroxisome proliferator treatment, as seen
ffectiveness of DHEA and DHEA-S by comparing the - PPARa sample with
igher dose is presumably due to the the + PPARa /vehicle control in Figure 2B.
t sulfation of DHEA in vivo, in a This finding suggests the existence of
catalyzed by liver sulfotransferases. endogenous activator(s) of PPARaC in
ctitionofPPARby DHEA-S COS-1 cells. Similar results have been
reported by others (23). PPARa-G, a
lated Steroids PPARa that has Glu282 Gly
;h manyforeign chemical peroxisome substitution, can substantially lower the
ators can activate PPARa to initiate basal activation while it remains sensitive to
hysiologic events, the physiologic peroxisome proliferator activation (38).
of PPARa activation are likely to Given this potentially greater sensitivity for
detection of aweakperoxisome proliferative
response using this mutant receptor,
PPARa-G was tested in transfection studies
to examine whether DHEA-S can induce a
low activation of PPAR. Figure 2B shows
that PPARa-G transfection results in a 6-
fold decrease in basal PPAR activation
when compared to wild-type PPARa, and
its activity was induced 30-fold after Wy-
14,643 treatment in the experiment shown.
However, no increase in reporter gene
activity could be detected in cells treated
with DHEA, 7-keto DHEA, DHEA-S, or
ADIOL-S, either in the absence (Figure 2B;
data not shown) or in the presence of
cotransfected RXR (data not shown).
To address the possibility that other
PPAR subtypes may mediate DHEA-S-
dependent peroxisome proliferator res-
ponses, cotransfection experiments have
been carried out using PPARy and PPAR6/
Nuci expression plasmids in the presence
of cotransfected RXRa. PPARy and
PPAR6/Nucl were found to be weakly
activated by high concentrations ofWy-
14,643 (100 1iM), in agreement with a pre-
vious report (39). However, DHEA,
DHEA-S, and ADIOL-S did not induce
significant responses from PPARy or
PPAR&/Nucl (22). Therefore, despite the
fact that DHEA-S is an active peroxisome
proliferator in vivoand in primary rat hepa-
tocytes, it is apparendy inactive with respect
to PPAR activation in transient transactiva-
tion assays using cultured cells that respond
to a wide range ofother PPAR activators
andperoxisome proliferators.
InfluenceofPPARaGeneKnockout
onDHEA-S-Induced Peroxisome
ProliferationinLiver
To probe the role ofPPARafor a DHEA-S-
stimulated peroxisome proliferative response
in vivo, PPARa knockout mice and wild-
type mice (5) were tested for their respon-
siveness to DHEA-S-induced peroxisome
proliferation. As we recently reported (22),
Western blot analysis ofliver microsomal
CYP4A revealed two CYP4A proteins that
were highly inducible in livers of PPARa
wild-type mice [PPARa (+/+)] mice when
treatedwith DHEA-S and clofibrate. In con-
trast, those same CYP4A proteins were not
induced by either clofibrate or DHEA-S
injection in PPARaknockout mice [PPARa
(-/-)] mice liver. A constitutively expressed
CYP4A immunoreactive protein ofslightly
lower apparent molecular weight was also
detected (Figure 3, band C), but its level was
unaffected by either peroxisome proliferator
or by the PPARa knockout phenotype
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Figure 3. Evaluation of DHEA-S induction of liver CYP4A proteins expression in PPARa (+/+) and PPARa (-/-)
mice. Western blotanalysis of liver microsome P4504A protein using anti-4A antibody. Microsomes were prepared
from liver samples corresponding to the samples shown in A P450 4A-immunoreactive proteins marked A and B
are induced by clofibrate and DHEA-S, but only in PPARa (+/+) mice, whereas band Ccorresponds to a constitu-
tively expressed protein that is unaffected bythe gene knockout.
(Figure 3). These results are consistent with
Northern blot results showing strong
increases in the hepatic mRNAs encoding
CYP4A1, CYP4A3, acyl-CoA-oxidase,
bifunctional enzyme, and 3-ketoacyl-CoA
thiolase in PPARa (+/+) mice but not
PPARa (-/-) mice after DHEA-S and
clofibrate treatment (22).
Thus, although DHEA-S is inactive
with respect to PPAR activation in tran-
sient trans-activation assays in COS-1 cells,
experiments carried out using a PPARa
gene knockout mouse model demonstrate
that PPARa is required for DHEA-S
induction ofhepatic peroxisome prolifera-
tion responses. These studies also indicate
that the peroxisome proliferative response
of DHEA-S is not mediated by two other
PPAR forms, PPARy and PPAR8/Nucl,
despite the presence ofthe latter nuclear
receptor at a significant level in liver tissue
(20,24). Several mechanisms could
explain the discrepancy between the find-
ings from the in vivo study and transient
cell transfection experiments: a) Other
factors that may be necessary for DHEA-S
induction of peroxisome proliferation in
vivo may be absent from the in vitro PPAR
trans-activation system. b) DHEA-S
might act in liver or other tissues to stimu-
late production of another endogenous
chemical that serves as a proximal PPARa
activator. c) The entry of DHEA-S into
cells may require a specific plasma mem-
brane transporter that is known to be pre-
sent in hepatocytes (40), but may be
absent in COS-1 and other cell types used
for PPAR transfection studies. Finally,
d) DHEA-S may be converted to an acti-
vated metabolite by a metabolic process
which occurs in hepatocytes but not in the
cell lines used for transfection studies.
In conclusion, the findings summarized
in this report establish that oxidized
metabolites ofTCE and other chlorinated
hydrocarbons, including TCA and DCA,
activate mouse PPARa. In vivo experiments
further establish that PPARa is an obliga-
tory mediator ofthe hepatic gene induction
effects ofthe endogenous steroidal peroxi-
some proliferator DHEA-S. Further investi-
gation will be necessary to elucidate any
interactions that may occur between
DHEA-S and chlorinated hydrocarbons at
the level ofreceptor activation, and to deter-
mine whether this potential for DHEA-S
and its metabolites to serve as physiologic
modulators ofliver fatty acid metabolism
and peroxisomal enzyme expression con-
tributes to the anticarcinogenic and other
beneficial chemoprotective properties of
this intriguing class ofendogenous steroids.
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